{'52WeekChange': 0.38214278,
 'SandP52WeekChange': 0.0644362,
 'address1': '7707 Gateway Boulevard',
 'address2': 'Suite 140',
 'algorithm': None,
 'annualHoldingsTurnover': None,
 'annualReportExpenseRatio': None,
 'ask': 15.48,
 'askSize': 1000,
 'averageDailyVolume10Day': 208437,
 'averageVolume': 1118719,
 'averageVolume10days': 208437,
 'beta': 1.387028,
 'beta3Year': None,
 'bid': 15.47,
 'bidSize': 800,
 'bookValue': 2.284,
 'category': None,
 'circulatingSupply': None,
 'city': 'Newark',
 'companyOfficers': [],
 'country': 'United States',
 'currency': 'USD',
 'dateShortInterest': 1593475200,
 'dayHigh': 16.66,
 'dayLow': 15.36,
 'dividendRate': None,
 'dividendYield': None,
 'earningsQuarterlyGrowth': None,
 'enterpriseToEbitda': -3.821,
 'enterpriseToRevenue': 139.746,
 'enterpriseValue': 323930240,
 'exDividendDate': None,
 'exchange': 'NGM',
 'exchangeTimezoneName': 'America/New_York',
 'exchangeTimezoneShortName': 'EDT',
 'expireDate': None,
 'fiftyDayAverage': 16.932142,
 'fiftyTwoWeekHigh': 19.67,
 'fiftyTwoWeekLow': 4.47,
 'fiveYearAverageReturn': None,
 'fiveYearAvgDividendYield': None,
 'floatShares': 21187000,
 'forwardEps': -1.97,
 'forwardPE': -7.8578677,
 'fromCurrency': None,
 'fullTimeEmployees': 80,
 'fundFamily': None,
 'fundInceptionDate': None,
 'gmtOffSetMilliseconds': '-14400000',
 'heldPercentInsiders': 0.03155,
 'heldPercentInstitutions': 0.9001,
 'industry': 'Biotechnology',
 'isEsgPopulated': False,
 'lastCapGain': None,
 'lastDividendValue': None,
 'lastFiscalYearEnd': 1577750400,
 'lastMarket': None,
 'lastSplitDate': None,
 'lastSplitFactor': None,
 'legalType': None,
 'logo_url': 'https://logo.clearbit.com/protagonist-inc.com',
 'longBusinessSummary': 'Protagonist Therapeutics, Inc., a clinical-stage '
                        'biopharmaceutical company, develops peptide-based '
                        'product candidates to address unmet medical needs in '
                        'hematology and gastroenterology. The company is '
                        'developing PTG-300, an injectable hepcidin mimetic '
                        'that is in Phase II clinical trial for the treatment '
                        'of patients with beta-thalassemia by targeting the '
                        'chronic anemia; PTG-200, an antagonist peptide '
                        'product candidate, which has completed Phase I '
                        'clinical trial to treat patients with '
                        "moderate-to-severe Crohn's disease; and PN-943, an "
                        'oral, alpha-4-beta-7 specific integrin antagonist '
                        'that is in Phase I clinical trial for treating '
                        'inflammatory bowel disease. It is also involved in '
                        'researching oral and injectable peptide-based product '
                        'candidates for a range of conditions, including '
                        'gastrointestinal diseases. The company has a license '
                        'and collaboration agreement with Janssen Biotech, '
                        'Inc. for the development, manufacture, and '
                        'commercialization of PTG-200 for the treatment of '
                        "Crohn's disease and ulcerative colitis. Protagonist "
                        'Therapeutics, Inc. was founded in 2006 and is '
                        'headquartered in Newark, California.',
 'longName': 'Protagonist Therapeutics, Inc.',
 'market': 'us_market',
 'marketCap': 552132864,
 'maxAge': 1,
 'maxSupply': None,
 'messageBoardId': 'finmb_129263324',
 'morningStarOverallRating': None,
 'morningStarRiskRating': None,
 'mostRecentQuarter': 1585612800,
 'navPrice': None,
 'netIncomeToCommon': -83164000,
 'nextFiscalYearEnd': 1640908800,
 'open': 16.12,
 'openInterest': None,
 'payoutRatio': 0,
 'pegRatio': None,
 'phone': '510 474 0170',
 'previousClose': 16.28,
 'priceHint': 2,
 'priceToBook': 6.777583,
 'priceToSalesTrailing12Months': 238.19365,
 'profitMargins': 0,
 'quoteType': 'EQUITY',
 'regularMarketDayHigh': 16.66,
 'regularMarketDayLow': 15.36,
 'regularMarketOpen': 16.12,
 'regularMarketPreviousClose': 16.28,
 'regularMarketPrice': 16.12,
 'regularMarketVolume': 207465,
 'revenueQuarterlyGrowth': None,
 'sector': 'Healthcare',
 'sharesOutstanding': 35667500,
 'sharesPercentSharesOut': 0.0369,
 'sharesShort': 1315818,
 'sharesShortPreviousMonthDate': 1590710400,
 'sharesShortPriorMonth': 1125379,
 'shortName': 'Protagonist Therapeutics, Inc.',
 'shortPercentOfFloat': 0.0424,
 'shortRatio': 2.29,
 'startDate': None,
 'state': 'CA',
 'strikePrice': None,
 'symbol': 'PTGX',
 'threeYearAverageReturn': None,
 'toCurrency': None,
 'totalAssets': None,
 'tradeable': False,
 'trailingAnnualDividendRate': None,
 'trailingAnnualDividendYield': None,
 'trailingEps': -3.109,
 'twoHundredDayAverage': 10.950432,
 'volume': 207465,
 'volume24Hr': None,
 'volumeAllCurrencies': None,
 'website': 'http://www.protagonist-inc.com',
 'yield': None,
 'ytdReturn': None,
 'zip': '94560'}